Open AccessTelithromycin Susceptibility and Genomic Diversity of Macrolide-Resistant Serotype III Group B Streptococci Isolated in Perinatal Infections
Author(s) -
Édouard Bingen,
Catherine Doit,
Philippe Bidet,
N. Brahimi,
Dominique Deforche
Publication year - 2004
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.48.2.677-680.2004
Subject(s) - telithromycin , erythromycin , microbiology and biotechnology , serotype , azithromycin , biology , clindamycin , group a , streptococcus pyogenes , group b , macrolide antibiotics , streptococcus pneumoniae , ketolide , virology , antibiotics , streptococcaceae , medicine , genetics , bacteria , staphylococcus aureus
We studied the telithromycin, erythromycin, azithromycin, and clindamycin susceptibilities of serotype III macrolide-resistant group B streptococci, together with genetic mechanisms of resistance and genomic diversity. ermB, ermA, and mefA were found in, respectively, 57, 32, and 9% of isolates. The telithromycin MIC at which 90% of isolates were inhibited was 0.5 micro g/ml. Macrolide resistance was associated with dissemination of resistance determinants among isolates of different genetic backgrounds.